Skip to main content
Premium Trial:

Request an Annual Quote

HealthLinx Announces Data Demonstrating Potential of Protein Marker as Ovarian Cancer Prognostic


Australian protein biomarker firm HealthLinx said this week it has completed a validation study assessing the potential prognostic value of an undisclosed protein biomarker for ovarian cancer.

According to the company, the marker was shown to be highly expressed in ovarian carcinoma tissue in patients with better clinical outcomes, with high expression associated with a 22 percent relapse rate compared to a 78 percent relapse rate in patients showing low expression.

Conducted at the Department of Anatomical Pathology at the Mater Health Services, Brisbane, the study used tissue microarrays from 200 patients comprising benign, malignant, and control samples. Expression of the marker was correlated with disease-free survival for up to 80 months.

The study "effectively positions the company to provide a vertical solution to the diagnosis of ovarian cancer with our OvPlex test and now potentially provide clinicians with an additional prognostic indicator with this novel biomarker," HealthLinx managing director Nick Gatsios said in a statement.

The company said it plans to disclose the marker and the research findings in a peer-reviewed publication "pending submission of new patent applications to cover the novel findings."

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.